Company intelligence / Profile preview

Starrygene Therapeutics

Ownership: Private
Development stage: Phase 1

Overview

Starrygene Therapeutics is developing AAV-based gene therapies primarily targeting ophthalmic diseases such as wet and dry age-related macular degeneration. Its lead candidate, XMVA09/XMVA09, is in early clinical trials for wAMD and has shown progress to at least Phase 1/early Phase 2. The company also has preclinical assets targeting other eye diseases and autoimmune/inflammatory conditions.

Therapeutic areas: EndocrinologyRheumatologyOphthalmology
Modalities: AAV-based gene therapy
Industry: Biotech

Partnerships

No major disclosed pharma or biotech partnerships found as of latest updates.

Beyond the preview

Go deeper on Starrygene Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Starrygene Therapeutics.

Explore the full profile